Vitalant’s Post

At the end of last year, Vertex/CRISPR and Bluebird received approvals on the same day for two different gene therapy products for sickle cell disease (SCD). Click the link below to download our most recent white paper and explore with our Cell and Gene Therapy experts, Subreen Khatib, Ph.D. and Sarah Jims, the approaches by each company to commercializing these complex technologies in this unique and quite interesting scenario. https://lnkd.in/eEhVZMjB #cellandgene #CGT

I had the pleasure of participating in a panel at #BIOEUROPE discussing the landscape of cell and gene therapy (CGT), focusing on its current status and emerging trends. It is fantastic to see the development of the CGT field and how many preclinical and clinical programs are underway to help patients with serious diseases. If you would like to learn more, check out #cellandgenetherapy #teambayer  #celltherapy #genetherapy #geneediting

Are you interested in learning more about: 🦠 Overcoming challenges in the industrialisation of iPSC-derived therapies? 🏥 UK patient referral pathways for gene therapy and CAR-T? 📝 How to develop a robust Target Product Profile (TPP) for your #ATMP? Take a look at our webinar recordings to hear from the experts at CGT Catapult addressing the key topics above and many more relating to the #cell and #gene therapy industry: https://buff.ly/3uE5HLS #CellTherapy #GeneTherapy #AdvancedTherapies #Innovation #Webinars

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx

Hear from Tom Smith today, at 11.30am (EST) at the Cell and Gene Therapy Pricing and Reimbursement Summit. Tom will be discussing how Uniphar are accelerating global patient access to cell and gene therapies. #CellandGeneTherapy #PricingReimbursement #MarketAccess #ExpandedAccess

Urgency... Perseverence... Determination.... Good things for all drug developers to keep in mind.... Fix this generation not just the next generation.... Are not rare diseases as the frontier for developing approaches to genetic disease --the most common of which may be Alzheimer's? We should all be cheering on the advances made--yes it's expensive, it's hard, it's "impossible" The first computers were the same way.... These are the pioneers finding out what could work for us all.... #GottaSolveThemAll #GottaSolveAllDisease #GeneticDiseaseIsOneTypeOfDisease #StillGreatIfYouCanSolveWithSmallMoleculesOrBiologics #TrikaftaApproachAmazingIfItWorks #DoNotKillThatOption #ButMayNotNeEasyOrStraightforword #GCLiveForeverClub #WeCanAllBeAPartOfIt #ScientistCanPlayASmallPartIn #HealingTheWorld #NoMoreDiseaseInducedMorbidityOrMortality #IsThisWhyThereIsOrWasSoMuchMarketExcitementInCrisprTechnologies #PublicSensesTheExcitementOfWhatCouldBePossible #DoesItMakeSenseAsAnInvestment #NotUnlessItWorks #ForNowThePOSMaySeemTooSmall #MechansimTooUnknown #WhatIfWeCanLive140Years #But70WithAlzheimers #NotGreat......

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx